Cuilian Guo

926 total citations
21 papers, 337 citations indexed

About

Cuilian Guo is a scholar working on Physiology, Otorhinolaryngology and Immunology and Allergy. According to data from OpenAlex, Cuilian Guo has authored 21 papers receiving a total of 337 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Physiology, 9 papers in Otorhinolaryngology and 9 papers in Immunology and Allergy. Recurrent topics in Cuilian Guo's work include Allergic Rhinitis and Sensitization (9 papers), Asthma and respiratory diseases (9 papers) and Sinusitis and nasal conditions (9 papers). Cuilian Guo is often cited by papers focused on Allergic Rhinitis and Sensitization (9 papers), Asthma and respiratory diseases (9 papers) and Sinusitis and nasal conditions (9 papers). Cuilian Guo collaborates with scholars based in China, Australia and United States. Cuilian Guo's co-authors include Zheng Liu, Bo Liao, Pan Li, Jia Song, Hai Wang, Jin‐Xin Liu, Yin Yao, Heng Wang, Ming Zeng and Guoping Wang and has published in prestigious journals such as Nature Communications, Journal of Allergy and Clinical Immunology and Trends in Immunology.

In The Last Decade

Cuilian Guo

18 papers receiving 334 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Cuilian Guo China 9 110 106 100 90 61 21 337
Xinni Xu Singapore 8 93 0.8× 69 0.7× 60 0.6× 33 0.4× 67 1.1× 25 245
Sebastian Ferri Italy 13 44 0.4× 268 2.5× 104 1.0× 22 0.2× 237 3.9× 29 489
Shivangi Lohia United States 10 160 1.5× 131 1.2× 141 1.4× 33 0.4× 104 1.7× 24 470
Chester C. Wood United States 14 19 0.2× 334 3.2× 280 2.8× 15 0.2× 136 2.2× 23 451
Marcello Cottini Italy 12 6 0.1× 309 2.9× 47 0.5× 38 0.4× 293 4.8× 29 426
Heqiong Wang United States 11 16 0.1× 62 0.6× 18 0.2× 16 0.2× 64 1.0× 22 361
Seyfettin Gümüş Türkiye 11 9 0.1× 73 0.7× 7 0.1× 145 1.6× 150 2.5× 32 387
Sarah Perusich United States 8 11 0.1× 85 0.8× 16 0.2× 10 0.1× 247 4.0× 11 352
Yuta Kono Japan 11 3 0.0× 144 1.4× 17 0.2× 86 1.0× 216 3.5× 29 362
Christian Ascoli United States 11 10 0.1× 160 1.5× 3 0.0× 42 0.5× 135 2.2× 32 326

Countries citing papers authored by Cuilian Guo

Since Specialization
Citations

This map shows the geographic impact of Cuilian Guo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cuilian Guo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cuilian Guo more than expected).

Fields of papers citing papers by Cuilian Guo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cuilian Guo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cuilian Guo. The network helps show where Cuilian Guo may publish in the future.

Co-authorship network of co-authors of Cuilian Guo

This figure shows the co-authorship network connecting the top 25 collaborators of Cuilian Guo. A scholar is included among the top collaborators of Cuilian Guo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cuilian Guo. Cuilian Guo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Guo, Cuilian, et al.. (2025). Postmarketing safety evaluation of belimumab: a pharmacovigilance analysis. Lupus Science & Medicine. 12(1). e001400–e001400.
2.
Guo, Cuilian, et al.. (2025). GZMK+CD8+ T cells: multifaceted roles beyond cytotoxicity. Trends in Immunology. 46(8). 562–572. 2 indexed citations
3.
Guo, Cuilian, Zhichao Wang, Feifan Liu, et al.. (2024). Granzyme K+CD8+ T cells interact with fibroblasts to promote neutrophilic inflammation in nasal polyps. Nature Communications. 15(1). 10413–10413. 19 indexed citations
4.
Guo, Cuilian, et al.. (2024). A Pharmacovigilance Analysis of Post-Marketing Safety of Tezepelumab. The Journal of Allergy and Clinical Immunology In Practice. 13(3). 551–558.e6.
5.
Wang, Nan, Jia Song, Jingxian Li, et al.. (2024). Immune signatures predict response to house dust mite subcutaneous immunotherapy in patients with allergic rhinitis. Allergy. 79(5). 1230–1241. 7 indexed citations
6.
Guo, Cuilian, et al.. (2024). Post-marketing safety of lorlatinib: a real-world study based on the FDA adverse event reporting system. Frontiers in Pharmacology. 15. 1385036–1385036. 3 indexed citations
7.
Liu, Jin‐Xin, Yibo Liu, Cuilian Guo, et al.. (2023). MEX3B inhibits collagen production in eosinophilic nasal polyps by downregulating epithelial cell TGFBR3 mRNA stability. JCI Insight. 8(9). 4 indexed citations
8.
Guo, Cuilian, Feifan Liu, De Yun Wang, & Zheng Liu. (2023). Type 2 Biomarkers for the Indication and Response to Biologics in CRSwNP. Current Allergy and Asthma Reports. 23(12). 703–713. 18 indexed citations
9.
Deng, Aiping, et al.. (2023). A real-world disproportionality analysis of mepolizumab based on the FDA adverse event reporting system. Frontiers in Pharmacology. 14. 1280490–1280490. 7 indexed citations
10.
Guo, Cuilian, et al.. (2023). Identification of Inflammatory Endotypes by Clinical Characteristics and Nasal Secretion Biomarkers in Chronic Rhinosinusitis with Nasal Polyps. International Archives of Allergy and Immunology. 184(10). 955–965. 5 indexed citations
11.
Song, Jia, Hai Wang, Cuilian Guo, et al.. (2023). Aberrant follicular regulatory T cells associate with immunoglobulin hyperproduction in nasal polyps with ectopic lymphoid tissues. Journal of Allergy and Clinical Immunology. 153(4). 1025–1039. 7 indexed citations
12.
Chen, Cailing, Cuilian Guo, Pan Li, et al.. (2022). Nasal secretion tissue plasminogen activator: A novel effective predictor of nasal polyp recurrence. The Journal of Allergy and Clinical Immunology In Practice. 10(8). 2191–2194.e3. 6 indexed citations
13.
Wang, Zhichao, Yin Yao, Cailing Chen, et al.. (2021). Extrafollicular PD-1highCXCR5–CD4+ T cells participate in local immunoglobulin production in nasal polyps. Journal of Allergy and Clinical Immunology. 149(2). 610–623. 23 indexed citations
14.
Guo, Cuilian, et al.. (2021). JNK downregulation improves olanzapine-induced insulin resistance by suppressing IRS1Ser307 phosphorylation and reducing inflammation. Biomedicine & Pharmacotherapy. 142. 112071–112071. 21 indexed citations
15.
Guo, Cuilian, et al.. (2021). Clinical and biological markers in disease and biologics to treat chronic rhinosinusitis. Current Opinion in Allergy and Clinical Immunology. 22(1). 16–23. 8 indexed citations
16.
Liu, Jin‐Xin, Zhen Zhen, Cuilian Guo, et al.. (2021). Endoplasmic reticulum stress promotes local immunoglobulin E production in allergic rhinitis. Laryngoscope Investigative Otolaryngology. 6(6). 1256–1266. 11 indexed citations
17.
Guo, Cuilian, et al.. (2020). Metformin ameliorates olanzapine-induced insulin resistance via suppressing macrophage infiltration and inflammatory responses in rats. Biomedicine & Pharmacotherapy. 133. 110912–110912. 28 indexed citations
18.
Li, Pan, Bo Liao, Cuilian Guo, et al.. (2020). Inflammatory features and predictors for postsurgical outcomes in patients with nasal polyps stratified by local and systemic eosinophilia. International Forum of Allergy & Rhinology. 11(5). 846–856. 23 indexed citations
19.
Liu, Jin‐Xin, Bo Liao, Hai Wang, et al.. (2019). The IL-37–Mex3B–Toll-like receptor 3 axis in epithelial cells in patients with eosinophilic chronic rhinosinusitis with nasal polyps. Journal of Allergy and Clinical Immunology. 145(1). 160–172. 33 indexed citations
20.
Liao, Bo, Heng Wang, Cuilian Guo, & Zheng Liu. (2017). [Sinonasal disease related to IgG4: one case report].. PubMed. 52(10). 777–778.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Xinni Xu Breakdown of academic impact, for papers by Sebastian Ferri Breakdown of academic impact, for papers by Shivangi Lohia Breakdown of academic impact, for papers by Chester C. Wood Breakdown of academic impact, for papers by Marcello Cottini Breakdown of academic impact, for papers by Heqiong Wang Breakdown of academic impact, for papers by Seyfettin Gümüş Breakdown of academic impact, for papers by Sarah Perusich Breakdown of academic impact, for papers by Yuta Kono Breakdown of academic impact, for papers by Christian Ascoli
Rankless by CCL
2026